Although some chronic hemolytic markers were found significantly modified for certain mesalamine formulations and oral budesonide compared with other formulations, the small number of IBD patients G6PD normal and deficient did not allow definitive conclusions or interpretations of the results. The gene discussed is G6PD; the disease is inflammatory bowel disease.